HIGHLIGHTS
- who: Top from the School of Biological Sciences, Ionis Pharmaceuticals, Carlsbad, California, USA have published the Article: Overcoming imatinib resistance conferred by the BIM deletion, in the Journal: (JOURNAL)
- what: The authors aimed to develop a therapeutic agent that could act directly and specifically (in a DNA sequence-specific manner) to correct the splice-switching defect produced by the BIM deletion. This work shows that it is possible to manipulate BIM alternative splicing to resensitize cancers to TKIs. end of this exon. The low levels of proapoptotic BIM associated to the deletion polymorphism render these . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.